The HIV prevention shot, lenacapavir, will be rolled out at South African clinics within the next couple of months and from 2027, the health department will also buy generics. But how best to spend the HIV prevention budget so that the country can drive infections down as fast as possible? We take a look at what the modelling data shows
After a year of US funding cuts across global public health, including South Africa’s hard-hit HIV programmes, new realities are settling in
We talked to experts in obesity, tobacco, artificial intelligence, HIV, TB and the NHI to find out what we can expect — and what we can’t — this year
Who should get what slice of the pie once the medicine is available in public clinics? And are numbers alone what would drive decisions?
None of the companies that will be involved have a licence from the inventor of Lenacapavir, Gilead Sciences, to make the jab
The country’s medicines regulator Sahpra says it’s on track to announce its registration decision by the end of October
The shot, called Lenacapavir, has a 100% success rate in preventing young women from getting HIV through sex
Hetero and Dr Reddy’s will be funded by the Gates Foundation and Unitaid to produce and sell the twice-a-year anti-HIV shot around R692 per person a year
CAB-LA virtually eliminates someone’s chances of contracting HIV, but costs about four times more than the government can afford to pay